PAH-Advance PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
- Coordinator
- Atxa Therapeutics Ltd, Ireland
- Runs
- 1 January 2023 to 31 December 2023
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €4.2m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190143893
What the project is doing
In the project's own words, from its summary on CORDIS.
ATXA Therapeutics has developed NTP42, a disruptive new drug for pulmonary arterial hypertension (PAH) and related cardiopulmonary (heart & lung) diseases. NTP42 blocks the thromboxane receptor, a target at the root cause of PAH & related diseases. By treating all clinical hallmarks in both the LUNGS and HEART, NTP42 offers a game-changing solution for PAH leading to its rapid adoption once marketed. ATXAs Phase I clinical trial showed NTP42 is safe & highly efficacious in man.
With EIC Blended Finance and VC co-investment, ATXA will undertake a Phase II trial on NTP42 in PAH. We will then secure a licensing deal with a pharma to ACCELERATE NTP42 to the PAH market (sales >$1B at 5 yrs post-launch & royalty returns to ATXA). With the proceeds of the licensing deal, we will DIVERSIFY uses of NTP42/pipeline drugs to treat other priority target diseases. This will also ENABLE growth (>100 FTEs), transforming ATXA into a major European pharma with a diversified diseases & drugs portfolio.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Atxa Therapeutics Ltd | Dublin | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI